Commentary
Clinical Pharmacology & Therapeutics (2007) 82, 248–250. doi:10.1038/sj.clpt.6100205
Protease Inhibitors as Immunomodulatory Drugs for HIV Infection
S G Deeks1
1University of California, San Francisco and San Francisco General Hospital, San Francisco, California, USA
Correspondence: SG Deeks, (sdeeks@php.ucsf.edu)
Top of page
Abstract
More than 20 drugs from four therapeutic drug classes are widely available for the management of human immunodeficiency virus (HIV) infection, with promising drugs from two new drug classes expected to be approved by the US Food and Drug Administration (FDA) in mid-to-late 2007 (Table 1). When used in combination, these drugs can lead to durable and perhaps indefinite suppression of viral replication.
